目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONAL SCOPE
1.3.3 INCLUSIONS AND EXCLUSIONS
1.3.4 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Objectives of secondary research
2.1.1.2 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primary interviews
2.1.2.2 Key objectives of primary research
2.2 MARKET ESTIMATION
2.2.1 GLOBAL MARKET ESTIMATION
2.2.1.1 Company revenue analysis (Bottom-up approach)
2.2.1.2 Revenue share analysis
2.2.1.3 MnM repository analysis
2.2.1.4 Primary interviews
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
2.3 GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 PHARMACEUTICAL EXCIPIENTS MARKET OVERVIEW
4.2 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET
4.3 PHARMACEUTICAL EXCIPIENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 PHARMACEUTICAL EXCIPIENTS MARKET: EMERGING VS. DEVELOPED MARKETS, 2025 VS. 2030 (USD MILLION)

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Surging demand for generic medications and pharmaceutical formulations.
5.2.1.2 Increased R&D investments to develop novel excipients
5.2.1.3 Growing focus on patient-centric drug formulations
5.2.1.4 Strategic collaborations and partnerships among pharmaceutical firms
5.2.2 RESTRAINTS
5.2.2.1 Strict and complex regulatory frameworks
5.2.2.2 High cost of excipient development and manufacturing
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing interest in functional and multifunctional excipients
5.2.3.2 Technological advancements in nanotechnology
5.2.3.3 Market opportunities in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Ongoing concerns about excipient safety and quality standards
5.2.4.2 Limited availability and fluctuating costs of key raw materials
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 INDICATIVE PRICING ANALYSIS, BY KEY PLAYER
5.4.2 INDICATIVE PRICING ANALYSIS, BY REGION
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Co-processed excipient technology
5.9.1.2 Nanotechnology-based excipients
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 3D printing/additive manufacturing
5.9.2.2 Process Analytical Technology (PAT)
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Artificial intelligence in formulation design
5.9.3.2 Green chemistry/sustainability tech
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 TRADE DATA FOR HS CODE 290545
5.11.1.1 Import data for HS code 290545
5.11.1.2 Export data for HS code 290545
5.11.2 TRADE DATA FOR HS CODE 350510
5.11.2.1 Import data for HS code 350510
5.11.2.2 Export data for HS code 350510
5.11.3 TRADE DATA FOR HS CODE 290532
5.11.3.1 Import data for HS code 290532
5.11.3.2 Export data for HS code 290532
5.11.4 TRADE DATA FOR HS CODE 283650
5.11.4.1 Import data for HS code 283650
5.11.4.2 Export data for HS code 283650
5.11.5 TRADE DATA FOR HS CODE 250100
5.11.5.1 Import data for HS code 250100
5.11.5.2 Export data for HS code 250100
5.11.6 TRADE DATA FOR HS CODE 290543
5.11.6.1 Import data for HS code 290543
5.11.6.2 Export data for HS code 290543
5.11.7 TRADE DATA FOR HS CODE 3912
5.11.7.1 Import data for HS code 3912
5.11.7.2 Export data for HS code 3912
5.12 KEY CONFERENCES AND EVENTS, 2025-2026
5.13 REGULATORY LANDSCAPE
5.13.1 REGULATORY FRAMEWORK
5.13.1.1 US
5.13.1.2 Europe
5.13.1.3 China
5.13.1.4 India
5.13.1.5 Brazil
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14 PORTER'S FIVE FORCES ANALYSIS
5.14.1 BARGAINING POWER OF SUPPLIERS
5.14.2 BARGAINING POWER OF BUYERS
5.14.3 THREAT OF NEW ENTRANTS
5.14.4 THREAT OF SUBSTITUTES
5.14.5 INTENSITY OF COMPETITIVE RIVALRY
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.15.2 KEY BUYING CRITERIA
5.16 IMPACT OF AI/GEN AI ON PHARMACEUTICAL EXCIPIENTS MARKET
5.16.1 INTRODUCTION
5.16.2 MARKET POTENTIAL OF AI ON PHARMACEUTICAL EXCIPIENTS
5.16.3 AI USE CASES
5.16.4 KEY COMPANIES IMPLEMENTING AI
5.16.5 FUTURE OF GENERATIVE AI IN PHARMACEUTICAL EXCIPIENT ECOSYSTEM
5.17 IMPACT OF 2025 US TARIFF ON PHARMACEUTICAL EXCIPIENTS MARKET
5.17.1 INTRODUCTION
5.17.2 KEY TARIFF RATES
5.17.3 PRICE IMPACT ANALYSIS
5.17.4 IMPACT ON COUNTRY/REGION
5.17.4.1 North America
5.17.4.1.1 US
5.17.4.2 Europe
5.17.4.3 Asia Pacific
5.17.5 IMPACT ON END-USE INDUSTRIES

6 PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 ORGANIC CHEMICALS
6.2.1 OLEOCHEMICALS
6.2.1.1 Fatty alcohols
6.2.1.1.1 Need for improved drug absorption to augment growth
6.2.1.2 Mineral stearates
6.2.1.2.1 Wide use of magnesium stearates as excipients in nutraceutical and pharmaceutical formulations to drive market
6.2.1.3 Glycerin
6.2.1.3.1 Non-toxic, colorless, and odorless properties to encourage growth
6.2.1.4 Other oleochemicals
6.2.2 CARBOHYDRATES
6.2.2.1 Sugars
6.2.2.1.1 Actual sugars
6.2.2.1.1.1 Growing use of actual sugars in pediatric formulations to propel market
6.2.2.1.1.2 Lactose
6.2.2.1.1.3 Sucrose
6.2.2.1.1.4 Dextrose (D-Glucose)
6.2.2.1.2 Sugar alcohols
6.2.2.1.2.1 Surging trend in consumer demand for healthier alternatives to conventional sweeteners to fuel market
6.2.2.1.2.2 Sorbitol
6.2.2.1.2.3 Mannitol
6.2.2.1.2.4 Other sugar alcohols
6.2.2.1.3 Artificial sweeteners
6.2.2.1.3.1 Increasing use of sugar substitutes to favor growth
6.2.2.2 Cellulose
6.2.2.2.1 Microcrystalline cellulose
6.2.2.2.1.1 Versatility, safety, and cost-effectiveness to facilitate growth
6.2.2.2.2 Cellulose ethers
6.2.2.2.2.1 Higher effectiveness than other water-soluble polymers to fuel market
6.2.2.2.3 CMC & croscarmellose sodium
6.2.2.2.3.1 Growing trend of sourcing CMC from more viable alternatives to boost market
6.2.2.2.4 Cellulose esters
6.2.2.2.4.1 Increasing focus on targeted and sustained-release drug delivery systems to sustain growth
6.2.2.3 Starch
6.2.2.3.1 Modified starch
6.2.2.3.1.1 Cold-water swelling and gel barrier formation capabilities to fuel market
6.2.2.3.2 Dried starch
6.2.2.3.2.1 Strong binding and coating properties to augment growth
6.2.2.3.3 Converted starch
6.2.2.3.3.1 Enhanced solubility and stability for drugs to foster growth
6.2.3 PETROCHEMICALS
6.2.3.1 Glycols
6.2.3.1.1 Polyethylene glycol
6.2.3.1.1.1 Solubility, lubricity, and compatibility with APIs to drive market
6.2.3.1.2 Propylene glycol
6.2.3.1.2.1 Rising use of propylene glycol in oral and injectable formulations to foster growth
6.2.3.2 Povidones
6.2.3.2.1 Increasing demand for fast-dissolving tablets to spur growth
6.2.3.3 Mineral hydrocarbons
6.2.3.3.1 Petrolatum
6.2.3.3.1.1 Strong presence in topical pharmaceutical formulations to expedite growth
6.2.3.3.2 Mineral waxes
6.2.3.3.2.1 Utilization of mineral waxes in solid and semi-solid dosage to foster growth
6.2.3.3.3 Mineral oils
6.2.3.3.3.1 Extensive use of mineral oils as solvents and emollients to propel market
6.2.3.4 Acrylic polymers
6.2.3.4.1 Wide use of acrylic polymers in controlled-release drug formulations to drive market
6.2.3.5 Other petrochemicals
6.2.4 PROTEINS
6.2.4.1 Growing applications of proteins as carriers for microparticles and nanoparticles to propel market
6.2.5 OTHER ORGANIC CHEMICALS
6.3 INORGANIC CHEMICALS
6.3.1 CALCIUM PHOSPHATE
6.3.1.1 Chemical purity and low incompatibility with drugs to aid growth
6.3.2 METAL OXIDES
6.3.2.1 Availability of silicon oxides in the hydrophobic, hydrophilic, and granulated forms to aid market growth
6.3.3 HALITES
6.3.3.1 Increased utilization of halites in vaccines and controlled-release formulations to foster growth
6.3.4 CALCIUM CARBONATE
6.3.4.1 Short disintegration time and excellent mechanical strength to expedite growth
6.3.5 CALCIUM SULFATE
6.3.5.1 High quality and cost effectiveness to aid growth
6.3.6 OTHER INORGANIC CHEMICALS
6.4 OTHER CHEMICALS

7 PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY
7.1 INTRODUCTION
7.2 FILLERS & DILUENTS
7.2.1 IMPROVED COHESION AND DIRECT COMPRESSION TO AMPLIFY GROWTH
7.3 SUSPENDING & VISCOSITY AGENTS
7.3.1 DRUG STABILITY AND TASTE MASKING ADVANTAGES TO SUSTAIN GROWTH
7.4 COATING AGENTS
7.4.1 INCREASING USE OF SUSTAINED-RELEASE FORMULATIONS IN PHARMA INDUSTRY TO DRIVE MARKET
7.5 BINDERS
7.5.1 HIGHER FLUIDITY AND COMPRESSIBILITY TO STIMULATE GROWTH
7.6 FLAVORING AGENTS & SWEETENERS
7.6.1 NEED TO IMPROVE DRUG PALATABILITY TO ADVANCE GROWTH
7.7 DISINTEGRANTS
7.7.1 NEED FOR RAPID BREAK-UP OF SOLID DOSAGE FORMS TO FOSTER GROWTH
7.8 COLORANTS
7.8.1 INCREASING USE OF COLORING IN HARD AND SOFT GELATIN CAPSULES, TABLETS, ORAL LIQUIDS, AND TOPICAL CREAMS TO BOOST MARKET
7.9 LUBRICANTS & GLIDANTS
7.9.1 NON-TOXIC PROPERTIES TO FAVOR GROWTH
7.10 PRESERVATIVES
7.10.1 GROWING USE OF PRESERVATIVES IN PHARMACEUTICAL AND NUTRACEUTICAL INDUSTRY TO DRIVE MARKET
7.11 EMULSIFYING AGENTS
7.11.1 RISING USE OF SOLUBILITY ENHANCEMENT EXCIPIENTS IN LIQUID DRUG FORMULATIONS TO PROMOTE GROWTH
7.12 OTHER FUNCTIONALITIES

8 PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION
8.1 INTRODUCTION
8.2 ORAL FORMULATIONS
8.2.1 TABLETS
8.2.1.1 High palatability and portability to support growth
8.2.2 CAPSULES
8.2.2.1 Hard-gelatin capsules
8.2.2.1.1 Ease of manufacturing and versatility to boost market
8.2.2.2 Soft-gelatin capsules
8.2.2.2.1 Quick-release properties to contribute to growth
8.2.3 LIQUID FORMULATIONS
8.2.3.1 Rapid absorption from stomach and intestines to foster growth
8.2.4 OTHER ORAL FORMULATIONS
8.3 TOPICAL FORMULATIONS
8.3.1 GROWING DEMAND FOR TRANSDERMAL PATCHES AND SELF-ADHERING TRANSDERMAL DRUG DELIVERY SYSTEMS TO FUEL MARKET
8.4 PARENTERAL FORMULATIONS
8.4.1 EMERGENCE OF BIOLOGICAL MOLECULES TO EXPEDITE GROWTH
8.5 OTHER FORMULATIONS

9 PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY APPLICATION
9.1 INTRODUCTION
9.2 STABILIZERS
9.2.1 IMPROVED DRUG SHELF LIFE AND LESSER MANUFACTURING DEFECTS TO PROMOTE GROWTH
9.3 TASTE MASKING
9.3.1 GROWING PREFERENCE FOR BETTER-TASTING SOLID DOSAGE FORMS TO PROPEL MARKET
9.4 MODIFIED-RELEASE
9.4.1 INCREASING USE OF MODIFIED-RELEASE FORMULATIONS IN PHARMA INDUSTRY TO FOSTER GROWTH
9.5 SOLUBILITY & BIOAVAILABILITY ENHANCEMENT
9.5.1 INCREASING PREFERENCE FOR SOLUBLE COMPOUNDS TO ACCELERATE GROWTH
9.6 OTHER APPLICATIONS

10 PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION
10.1 INTRODUCTION
10.2 EUROPE
10.2.1 MACROECONOMIC ANALYSIS FOR EUROPE
10.2.2 GERMANY
10.2.2.1 Booming pharmaceutical manufacturing sector to aid growth
10.2.3 UK
10.2.3.1 Growing adoption of generics and development of novel excipients to fuel market
10.2.4 FRANCE
10.2.4.1 Large geriatric population to support growth
10.2.5 ITALY
10.2.5.1 Budgetary constraints and restricted healthcare spending to impede growth
10.2.6 SPAIN
10.2.6.1 High consumption of biologics to foster growth
10.2.7 REST OF EUROPE
10.3 NORTH AMERICA
10.3.1 MACROECONOMIC ANALYSIS FOR NORTH AMERICA
10.3.2 US
10.3.2.1 Well-developed healthcare infrastructure and research bases to aid growth
10.3.3 CANADA
10.3.3.1 Rising prevalence of cancer to contribute to growth
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC ANALYSIS FOR ASIA PACIFIC
10.4.2 CHINA
10.4.2.1 Emphasis on generics and off-patent drugs to drive market
10.4.3 JAPAN
10.4.3.1 Rapid growth of elderly population to augment growth
10.4.4 INDIA
10.4.4.1 High domestic demand for pharmaceuticals and export volume to boost market
10.4.5 SOUTH KOREA
10.4.5.1 Presence of leading contract research and development organizations to propel market
10.4.6 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 GROWING GERIATRIC POPULATION AND RISING DISEASE PREVALENCE ARE DRIVING MARKET GROWTH
10.5.2 MACROECONOMIC ANALYSIS FOR LATIN AMERICA
10.5.3 BRAZIL
10.5.3.1 Emerging opportunities for excipient manufacturers to drive market
10.5.4 MEXICO
10.5.4.1 Growing demand for affordable therapies to boost market
10.5.5 REST OF LATIN AMERICA
10.6 MIDDLE EAST
10.6.1 GROWING FOCUS ON UNSATURATED MARKETS TO DRIVE MARKET
10.6.2 MACROECONOMIC ANALYSIS FOR MIDDLE EAST
10.6.3 GCC COUNTRIES
10.6.3.1 Expanding healthcare infrastructure expansion and localization of drug manufacturing to bolster growth
10.6.4 REST OF MIDDLE EAST
10.7 AFRICA
10.7.1 INCREASING PRESENCE OF MAJOR PHARMACEUTICAL COMPANIES TO AUGMENT GROWTH
10.7.2 MACROECONOMIC ANALYSIS FOR AFRICA

11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PHARMACEUTICAL EXCIPIENTS MARKET, 2022-2024
11.3 REVENUE ANALYSIS, 2020-2024
11.4 MARKET SHARE ANALYSIS, 2024
11.5 COMPANY VALUATION AND FINANCIAL METRICS
11.6 BRAND/PRODUCT COMPARISON
11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.7.1 STARS
11.7.2 EMERGING LEADERS
11.7.3 PERVASIVE PLAYERS
11.7.4 PARTICIPANTS
11.7.5 COMPETITIVE BENCHMARKING: KEY PLAYERS, 2024
11.7.5.1 Company footprint
11.7.5.2 Region footprint
11.7.5.3 Product footprint
11.7.5.4 Functionality footprint
11.7.5.5 Functionality application footprint
11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
11.8.1 PROGRESSIVE COMPANIES
11.8.2 RESPONSIVE COMPANIES
11.8.3 DYNAMIC COMPANIES
11.8.4 STARTING BLOCKS
11.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
11.8.5.1 Detailed list of key startups/SMEs
11.8.5.2 Competitive benchmarking of key startups/SMEs
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES AND APPROVALS
11.9.2 DEALS
11.9.3 EXPANSIONS

12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 INTERNATIONAL FLAVORS & FRAGRANCES INC.
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 Recent developments
12.1.1.3.1 Deals
12.1.1.3.2 Expansions
12.1.1.4 MnM view
12.1.1.4.1 Key strengths
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses and competitive threats
12.1.2 ADM
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 Recent developments
12.1.2.3.1 Deals
12.1.2.4 MnM view
12.1.2.4.1 Key strengths
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses and competitive threats
12.1.3 ROQUETTE FRERES
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 Recent developments
12.1.3.3.1 Product launches and approvals
12.1.3.4 MnM view
12.1.3.4.1 Key strengths
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses and competitive threats
12.1.4 BASF SE
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 Recent developments
12.1.4.3.1 Deals
12.1.4.3.2 Expansions
12.1.4.4 MnM view
12.1.4.4.1 Key strengths
12.1.4.4.2 Strategic choices
12.1.4.4.3 Weaknesses and competitive threats
12.1.5 EVONIK
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.3.1 Expansions
12.1.5.4 MnM view
12.1.5.4.1 Key strengths
12.1.5.4.2 Strategic choices
12.1.5.4.3 Weaknesses and competitive threats
12.1.6 ASHLAND
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.6.3 Recent developments
12.1.6.3.1 Product launches and approvals
12.1.7 KERRY GROUP PLC
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.7.3 Recent developments
12.1.7.3.1 Deals
12.1.8 MERCK
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.8.3 Recent developments
12.1.8.3.1 Deals
12.1.9 ASSOCIATED BRITISH FOODS PLC
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.9.3 Recent developments
12.1.9.3.1 Deals
12.1.10 WACKER CHEMIE AG
12.1.10.1 Business overview
12.1.10.2 Products offered
12.1.11 AIR LIQUIDE
12.1.11.1 Business overview
12.1.11.2 Products offered
12.1.11.3 Recent developments
12.1.11.3.1 Product launches and approvals
12.1.12 DOW
12.1.12.1 Business overview
12.1.12.2 Products offered
12.1.13 BERKSHIRE HATHAWAY (LUBRIZOL CORPORATION)
12.1.13.1 Business overview
12.1.13.2 Products offered
12.1.13.3 Recent developments
12.1.13.3.1 Product launches and approvals
12.1.14 COLORCON, INC.
12.1.14.1 Business overview
12.1.14.2 Products offered
12.1.14.3 Recent developments
12.1.14.3.1 Product launches and approvals
12.1.14.3.2 Deals
12.1.14.3.3 Expansions
12.1.15 DFE PHARMA
12.1.15.1 Business overview
12.1.15.2 Products offered
12.1.15.3 Recent developments
12.1.15.3.1 Deals
12.1.16 ACTYLIS
12.1.16.1 Business overview
12.1.16.2 Products offered
12.1.16.3 Recent developments
12.1.16.3.1 Deals
12.1.17 CRODA INTERNATIONAL PLC
12.1.17.1 Business overview
12.1.17.2 Products offered
12.1.17.3 Recent developments
12.1.17.3.1 Deals
12.1.17.3.2 Expansions
12.1.18 CHEMIE TRADE
12.1.18.1 Business overview
12.1.18.2 Products offered
12.1.19 GATTEFOSSE
12.1.19.1 Business overview
12.1.19.2 Products offered
12.1.20 J. RETTENMAIER & SOHNE GMBH + CO KG
12.1.20.1 Business overviewn
12.1.20.2 Products offered
12.1.21 SHIN-ETSU CHEMICAL CO., LTD.
12.1.21.1 Business overview
12.1.21.2 Products offered
12.1.21.3 Recent developments
12.1.21.3.1 Deals
12.1.21.3.2 Expansions
12.2 OTHER PLAYERS
12.2.1 INNOPHOS
12.2.2 MEGGLE GMBH & CO. KG
12.2.3 FUJI CHEMICAL INDUSTRIES CO., LTD.
12.2.4 COREL PHARMA CHEM
12.2.5 BIOGRUND
12.2.6 NITIKA PHARMACEUTICAL SPECIALTIES PVT. LTD.
12.2.7 R.T. VANDERBILT HOLDING COMPANY, INC.
12.2.8 BENEO
12.2.9 SIAGACHI INDUSTRIES
12.2.10 JH NANHANG LIFE SCIENCES CO., LTD.

13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS